Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.

BACKGROUND: To estimate the risk of type 1 diabetes associated with immune checkpoint inhibitor (ICI-T1DM), and to describe its clinical features. METHODS: ICI-T1DM events in randomized clinical trials (RCTs) available in electronic databases were systematically reviewed. The primary outcome was the summary risk of T1DM related to ICIs, a meta-analysis was conducted to obtain Peto odds ratios (ORs) with 95 % CIs. In pharmacovigilance study, ICI-T1DM cases were extracted from FAERs. Disproportionality analyses were performed by calculating reporting odds ratio (ROR) and information components (IC). RESULTS: A total of 29 RCTs (20,234 patients) were included, treatment with ICIs significantly increased the risk of all-grade ICI-T1DM (OR: 4.54, 95 % CI: 2.66-7.72), and high-grade (grade 3 or above) ICI-T1DM (OR: 4.26, 95 % CI: 2.12-8.58). No significant differences among subgroup analyses were observed: ICIs treatment schedule, tumor type, case of events (T1DM vs F-T1DM), study design (double blind vs open label) or median PFS (PFS favours ICIs vs PFS favours Control). A total of 978 case reports form FAERS was extracted, treatment with ICIs significantly increased the reporting of ICI-T1DM (n = 978; ROR = 38.45, 95 %CI:35.70-41.41; IC = 4.77, 95 %CI:4.43-5.14). In cases with available data, the median latency period was 10.4 weeks, drug interruption was recorded in 82.3 % of cases, with a positive dechallenge in 76 % of cases, and death was recorded as outcome in 3.6 % of reports. CONCLUSIONS: Both data from clinical trials and postmarketing suggested that ICIs was associated with increased risk of ICI-T1DM. As ICIs gain greater clinical use, practitioners must be aware of ICI-T1DM events.

Microbubbles: A Novel Strategy for Chemotherapy.

BACKGROUND: Ultrasound microbubbles have conventionally been used for diagnostic purposes. In recent years, however, new types of microbubbles have emerged as important carriers for drug delivery. Moreover, studies have shown that ultrasound microbubbles can serve as valuable and noninvasive tools in cancer therapy; thus the use of ultrasound microbubbles to deliver chemotherapeutic drugs to malignant tissues is a promising possibility. METHODS: In this review, we briefly describe the status of ultrasound microbubbles in clinical practice and then discuss the development of targeted microbubbles. Finally, we consider novel strategies for the use of microbubbles in cancer therapy. RESULTS: Many different kinds of microbubbles are emerged. Novel strategies of ultrasound microbubble have been shown to be effective in cancer therapy. CONCLUSION: Although many problems need to be solved in the future, the ultrasound drugs loaded microbubbles still have strong potential for the use in clinical cancer therapy.

Shape and Composition Effects on Photocatalytic Hydrogen Production for Pt-Pd Alloy Cocatalysts.

The shape and composition effects of platinum-palladium (Pt-Pd) alloy nanoparticle cocatalysts on visible-light photocatalytic hydrogen evolution from an aqueous ammonium sulphite solution have been reported and discussed. The activity of Pt-Pd nanoparticles loaded Pt-Pd/CdS photocatalysts are affected based on both the Pt-Pd alloy nanoparticles' shape and their compositions. In this research, two shapes of Pt-Pd nanoparticles have been studied. One is Pt-Pd nanocubes enclosed by {100} crystal planes and the other is nano-octahedra covered with {111} crystal facets. Results show that the photocatalytic turnover frequency (TOF), defined as moles of hydrogen produced per surface mole of Pt-Pd metal atom per second, for Pt-Pd nanocubes/CdS (Pt-Pd NCs/CdS) photocatalyst can be 3.4 times more effective than Pt-Pd nano-octahedra/CdS (Pt-Pd NOTa/CdS) nanocomposite photocatalyst. Along with the shape effect, the atomic ratio of Pt to Pd can also impact the efficiency of Pt-Pd/CdS photocatalysts. When the Pt to Pd atomic ratio changes from 1:0 to about 2:1, the rate of hydrogen production increases from 900 µmol/h for Pt NCs/CdS catalyst to 1837 µmol/h for Pt-Pd (2:1) NCs/CdS photocatalyst-a 104% rate increase. This result suggests that the 33 mol % of more expensive Pt can be replaced with less costly Pd, resulting in a more than 100% hydrogen production rate increase. The finding of this research will lead to the research and development of highly effective catalysts for photocatalytic hydrogen production using solar photonic energy.